Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company AnaptysBio Inc.
DescriptionAnti-TIM3 antagonist mAb
Molecular Target T cell immunoglobulin and mucin domain 3 (TIM3) (HAVCR2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
PartnerTesaro Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today